Liso-cel Leads to High CR Rate in Follicular Lymphoma

Liso-cel achieved high complete response (CR) rates, deep and durable remissions, and a favorable safety profile in patients with second-line relapsed or refractory follicular lymphoma (FL), according to an abstract presented at the 65th American Society of Hematology Annual Meeting & Exposition.

Led by Franck Morschhauser, PhD, of the Hospital Claude Huriez in Lille, France, the abstract presented data from the phase II TRANSCEND FL trial. All 23 evaluable patients in the 2L relapsed or refractory FL cohort had one prior combination systemic therapy with an anti-CD20 antibody and alkylator, and received liso-cel at 100 × 10⁶ CAR⁺ T cells.

Liso-cel achieved high overall response and CR rates in 22 of 23 (95.7%) patients. The median duration of response (DOR) and progression-free survival (PFS) were not reached after a median follow-up of 16.8 months and 17.8 months, respectively. Meanwhile, the 12-month DOR and PFS were 89.8% and 91.3%, respectively.

Cytopenias were the most common grade ≥ 3 treatment-emergent adverse events, with neutropenia being the most frequent. Cytokine release syndrome occurred in 12 (52%) patients.

“These data support liso-cel as a potential new treatment option in [patients] with 2L [relapsed or refractory] FL at high-risk for treatment failure,” the researchers concluded.

Reference

Morschhauser F, Dahiya S, Palomba M, et al. TRANSCEND FL: phase 2 study primary analysis of lisocabtagene maraleucel as second-line therapy in patients with high-risk relapsed or refractory follicular lymphoma. Abstract #602. Presented at the 65th ASH Annual Meeting and Exposition; December 9-12, 2023; San Diego, California.